These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 30660796)
1. Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. Dagogo-Jack I; Robinson H; Mino-Kenudson M; Farago AF; Kamesan V; Iafrate AJ; Shaw AT; Lennerz JK J Thorac Oncol; 2019 May; 14(5):835-843. PubMed ID: 30660796 [TBL] [Abstract][Full Text] [Related]
2. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908 [TBL] [Abstract][Full Text] [Related]
3. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer. Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871 [TBL] [Abstract][Full Text] [Related]
4. Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments. Coquerelle S; Darlington M; Michel M; Durand M; Borget I; Baffert S; Marino P; Perrier L; Durand-Zaleski I; Value Health; 2020 Jul; 23(7):898-906. PubMed ID: 32762992 [TBL] [Abstract][Full Text] [Related]
5. Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments. Zugazagoitia J; Rueda D; Carrizo N; Enguita AB; Gómez-Sánchez D; Díaz-Serrano A; Jiménez E; Mérida A; Calero R; Lujan R; De Miguel E; Gámez P; Díaz-Hellín V; Nuñez JA; Iglesias L; Ferrer I; Paz-Ares L; Ponce-Aix S Clin Lung Cancer; 2018 Jan; 19(1):65-73.e7. PubMed ID: 28780976 [TBL] [Abstract][Full Text] [Related]
7. Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer. Lee YJ; Kim D; Kim HS; Na K; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT Yonsei Med J; 2019 Oct; 60(10):914-923. PubMed ID: 31538426 [TBL] [Abstract][Full Text] [Related]
8. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer. Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949 [TBL] [Abstract][Full Text] [Related]
9. Chromosomal microarray provides enhanced targetable gene aberration detection when paired with next generation sequencing panel in profiling lung and colorectal tumors. Mukherjee S; Ma Z; Wheeler S; Sathanoori M; Coldren C; Prescott JL; Kozyr N; Bouzyk M; Correll M; Ho H; Chandra PK; Lennon PA Cancer Genet; 2016 Apr; 209(4):119-29. PubMed ID: 26880400 [TBL] [Abstract][Full Text] [Related]
10. The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer. Laufer-Geva S; Rozenblum AB; Twito T; Grinberg R; Dvir A; Soussan-Gutman L; Ilouze M; Roisman LC; Dudnik E; Zer A; Rotem O; Lanman RB; Peled N J Thorac Oncol; 2018 Nov; 13(11):1705-1716. PubMed ID: 30121392 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive Genomic Profiling of Malignant Effusions in Patients with Metastatic Lung Adenocarcinoma. Yang SR; Lin CY; Stehr H; Long SR; Kong CS; Berry GJ; Zehnder JL; Kunder CA J Mol Diagn; 2018 Mar; 20(2):184-194. PubMed ID: 29269277 [TBL] [Abstract][Full Text] [Related]
12. Clinical Utility of Rapid Dagogo-Jack I; Azzolli CG; Fintelmann F; Mino-Kenudson M; Farago AF; Gainor JF; Jiang G; Piotrowska Z; Heist RS; Lennes IT; Temel JS; Mooradian MJ; Lin JJ; Digumarthy SR; Batten JM; Robinson H; Nose V; Rivera M; Nardi V; Dias-Santagata D; Le LP; Sequist LV; Pitman M; Shepard JO; Shaw AT; Iafrate AJ; Lennerz JK JCO Precis Oncol; 2018; 2018():. PubMed ID: 30370396 [TBL] [Abstract][Full Text] [Related]
13. Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. Takeda M; Sakai K; Terashima M; Kaneda H; Hayashi H; Tanaka K; Okamoto K; Takahama T; Yoshida T; Iwasa T; Shimizu T; Nonagase Y; Kudo K; Tomida S; Mitsudomi T; Saigo K; Ito A; Nakagawa K; Nishio K Ann Oncol; 2015 Dec; 26(12):2477-82. PubMed ID: 26420428 [TBL] [Abstract][Full Text] [Related]
14. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice. Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127 [TBL] [Abstract][Full Text] [Related]
15. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program. Mantripragada KC; Olszewski AJ; Schumacher A; Perez K; Birnbaum A; Reagan JL; Mega A; Khurshid H; Bartley C; Lombardo A; Rossiter R; Papa A; Bakalarski P; Safran H J Oncol Pract; 2016 Apr; 12(4):e396-404. PubMed ID: 26907448 [TBL] [Abstract][Full Text] [Related]
16. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing. Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823 [TBL] [Abstract][Full Text] [Related]
17. Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences. Cho M; Ahn S; Hong M; Bang H; Van Vrancken M; Kim S; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Sun JM; Lee SH; Ahn MJ; Park K; Kim DH; Lee S; Park W; Kim KM Oncotarget; 2017 Jun; 8(26):42478-42486. PubMed ID: 28477007 [TBL] [Abstract][Full Text] [Related]
18. Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy. Garcia-Pardo M; Czarnecka K; Law JH; Salvarrey A; Fernandes R; Fan J; Corke L; Waddell TK; Yasufuku K; Donahoe LL; Pierre A; Le LW; Ghumman N; Liu G; Shepherd FA; Bradbury P; Sacher A; Stockley T; Pal P; Rogalla P; Tsao MS; Leighl NB Ther Adv Med Oncol; 2022; 14():17588359221126151. PubMed ID: 36158638 [TBL] [Abstract][Full Text] [Related]
19. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies. Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793 [TBL] [Abstract][Full Text] [Related]
20. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). Flaherty KT; Gray RJ; Chen AP; Li S; McShane LM; Patton D; Hamilton SR; Williams PM; Iafrate AJ; Sklar J; Mitchell EP; Harris LN; Takebe N; Sims DJ; Coffey B; Fu T; Routbort M; Zwiebel JA; Rubinstein LV; Little RF; Arteaga CL; Comis R; Abrams JS; O'Dwyer PJ; Conley BA; J Clin Oncol; 2020 Nov; 38(33):3883-3894. PubMed ID: 33048619 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]